Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19965961 | 0.94 | KDM4E (0.34) | LMNAALDH1A1GAACYP1A2KDM4E | |
| SCHEMBL19959839 | 0.94 | KDM4E (0.34) | LMNAALDH1A1USP2GAATSHR | |
| SCHEMBL19959793 | 0.92 | KDM4E (0.35) | LMNAALDH1A1USP2GAATSHR | |
| SCHEMBL19965960 | 0.90 | KDM4E (0.32) | LMNAALDH1A1USP2GAATSHR | |
| SCHEMBL19959909 | 0.89 | USP2 (0.31) | LMNAALDH1A1USP2GAATSHR | |
| SCHEMBL19959794 | 0.88 | CYP2C9 (0.35) | ALDH1A1 | |
| SCHEMBL19959925 | 0.87 | ALDH1A1 (0.34) | LMNAALDH1A1USP2GAATSHR | |
| SCHEMBL19959923 | 0.86 | KDM4E (0.34) | LMNAALDH1A1USP2GAATSHR | |
| SCHEMBL19959926 | 0.85 | MAPT (0.34) | LMNAALDH1A1GAATSHRCYP1A2 | |
| SCHEMBL19959931 | 0.85 | KDM4E (0.32) | LMNAALDH1A1USP2GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10700289-B2 | Heterocyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2020-06-30 | — | — | US | disclosed |
| US-20180076395-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-03-15 | — | — | US | disclosed |
| US-20180076395-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180076395-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | CRY1, CRY2, PER2 | LMNA 3023/4885ALDH1A1 750/4885USP2 2746/4885 |
| US-10700289-B2 | Heterocyclic compound and organic light emitting element comprising same | CRY1, CRY2, PER2 | LMNA 3023/4885ALDH1A1 750/4885USP2 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.